PMID- 27000732
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20210102
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 53
IP  - 2
DP  - 2016 Apr
TI  - Haploidentical bone marrow and stem cell transplantation: experience with 
      post-transplantation cyclophosphamide.
PG  - 90-7
LID - S0037-1963(16)00006-8 [pii]
LID - 10.1053/j.seminhematol.2016.01.005 [doi]
AB  - Allogeneic blood or bone marrow transplantation (BMT) is a potentially curative 
      therapy for high-risk hematologic malignancies not curable by standard 
      chemotherapy, but the procedure is limited by the availability of human leukocyte 
      antigen-matched donors for many patients, as well as toxicities including 
      graft-versus-host disease (GVHD). Our group has developed the use of high-dose 
      post-transplantation cyclophosphamide (PTCy) to selectively remove alloreactive T 
      cells without compromising engraftment. This protocol has allowed for successful 
      transplantation of human leukocyte antigen (HLA)-haploidentical (haplo) grafts, 
      thus expanding the donor pool for the many patients who would not otherwise be a 
      candidate for this life-saving procedure. In this review we will summarize the 
      data that led to the development of PTCy, then focus on the outcomes of haploBMT 
      trials with PTCy across different transplant platforms for patients with 
      malignant hematologic diseases, and finally we will discuss emerging evidence 
      that suggests equivalency of haploBMT with PTCy compared with more traditional 
      transplants.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Robinson, Tara M
AU  - Robinson TM
AD  - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Oncology; 
      Johns Hopkins University School of Medicine, Baltimore, MD.
FAU - O'Donnell, Paul V
AU  - O'Donnell PV
AD  - Massachusetts General Hospital Cancer Center, Boston, MA.
FAU - Fuchs, Ephraim J
AU  - Fuchs EJ
AD  - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Oncology; 
      Johns Hopkins University School of Medicine, Baltimore, MD.
FAU - Luznik, Leo
AU  - Luznik L
AD  - Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Oncology; 
      Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: 
      luznile@jhmi.edu.
LA  - eng
GR  - P01 CA015396/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160115
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - *Bone Marrow Transplantation
MH  - Cyclophosphamide/*therapeutic use
MH  - Graft vs Host Disease/immunology
MH  - Haploidy
MH  - Hematologic Neoplasms/therapy
MH  - Humans
MH  - *Stem Cell Transplantation
PMC - PMC4806368
MID - NIHMS752194
OTO - NOTNLM
OT  - Bone marrow transplant
OT  - GVHD prophylaxis
OT  - Haploidentical
OT  - Post-transplant cyclophosphamide
COIS- The authors declare that they have no conflicts of interest or competing 
      financial or personal relationships that could inappropriately influence the 
      content of this article.
EDAT- 2016/03/24 06:00
MHDA- 2016/09/13 06:00
PMCR- 2017/04/01
CRDT- 2016/03/23 06:00
PHST- 2016/03/23 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - S0037-1963(16)00006-8 [pii]
AID - 10.1053/j.seminhematol.2016.01.005 [doi]
PST - ppublish
SO  - Semin Hematol. 2016 Apr;53(2):90-7. doi: 10.1053/j.seminhematol.2016.01.005. Epub 
      2016 Jan 15.